Content - Detail

Bayer forms Alliance with Kyoto University

  • 2014/10/27

Bayer HealthCare and Kyoto University’s Office of Society–Academia Collaboration for Innovation der Universität Kyoto (KU-SACI) have signed a two-year collaboration agreement on October 24th to jointly identify candidates for possible collaborative research projects. The partners will focus on key areas of worldwide unmet medical need such as cardiology, oncology, hematology, gynecology, and ophthalmology.

Foto: Bayer

This collaboration is part of Bayer’s overall approach to partner with external partners from academia and industry to discover and develop new treatment options for patients worldwide. Recently launched collaborations include for example the strategic research alliance in the area of gynecological therapies with the University of Oxford, UK, or with Dimension Therapeutics for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Furthermore, Bayer has established two research incubators for young life sciences companies in the context of its open innovation approach. Dubbed “CoLaborator” at Bayer’s research and development sites in San Francisco’s Mission Bay, USA, and Berlin, Germany, these research incubators create an ideal environment in which to advance research and innovation.

The agreement with KU-SACI aims at jointly leveraging Kyoto University’s expertise and innovative approaches in diverse research areas and combining it with Bayer’s expertise in drug discovery and development. The endeavor will be supported by Bayer’s newly established “Open Innovation Center Japan” (ICJ) in Osaka, Japan.

Press Release: Bayer HealthCare

RSS Feed

The following "Research in Germany" RSS Feed contains the latest press releases from more than 70 German R & D institutions: